Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer

Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms

(2017) Danae A Delivanis et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism

(2017) David J. Stott et al.   NEW ENGLAND JOURNAL OF MEDICINE

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

(2016) J. Naidoo et al.   ANNALS OF ONCOLOGY

Antibody-Mediated Thyroid Dysfunction During T-cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer

(2016) J.C. Osorio et al.   ANNALS OF ONCOLOGY

Endocrinological side-effects of immune checkpoint inhibitors

(2016) Francesco Torino et al.   CURRENT OPINION IN ONCOLOGY

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

(2016) J.M. Michot et al.   EUROPEAN JOURNAL OF CANCER

Optimal design and endpoint of clinical trials using immune checkpoint blocking agents

(2016) Bhumsuk Keam et al.   Expert Review of Anticancer Therapy

Anti–PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy

(2016) Gautam Kishore Valecha et al.   Expert Review of Anticancer Therapy

Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab

(2016) Jeroen de Filette et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Classifying Cancers Based on T-cell Infiltration and PD-L1

(2015) Michele W.L. Teng et al.   CANCER RESEARCH

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

(2015) M. Freeman-Keller et al.   CLINICAL CANCER RESEARCH

Induction of Painless Thyroiditis in Patients Receiving Programmed Death 1 Receptor Immunotherapy for Metastatic Malignancies

(2015) Steven Orlov et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis

(2015) Hansje-Eva Teulings et al.   JOURNAL OF CLINICAL ONCOLOGY

Bypassing checkpoints, overcoming resistance and honing in on new targets

(2015) Egbert F. Smit et al.   Nature Reviews Clinical Oncology

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Clinical characteristics and treatment-related biomarkers associated with response to high-dose interleukin-2 in metastatic melanoma and renal cell carcinoma: retrospective analysis of an academic community hospital’s experience

(2015) Christine Saraceni et al.   SpringerPlus

Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution

(2014) Mabel Ryder et al.   ENDOCRINE-RELATED CANCER

Skin Rash could Predict the Response to EGFR Tyrosine Kinase Inhibitor and the Prognosis for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

(2013) Hong-bing Liu et al.   PLoS One

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH